| The BBL CHROMagar MRSA utilizes a new chromogenic technology which permits the detection of MRSA using chromogenic substrates and a cephalosporin. MRSA strains will grow in the presence of antibiotics and produce mauve-colored colonies resulting from hydrolysis of the chromogenic substrates. In clinical evaluations, BBL CHROMagar MRSA displayed 8% greater recovery¹ of MRSA than traditional screening algorithm and has the capability to identify MRSA earlier than most traditional algorithms. This unique technology requires less technologist time and improves the workflow in the laboratory. BBL CHROMagar MRSA allows for the direct detection and identification of most MRSA within 24 hours, or at 48 hours with a confirmatory test.
"This technology will be extremely useful to those who wish to identify patients colonized with MRSA," said Dr. Bill Jarvis of Emory University School of Medicine and President, Jason and Jarvis Associates. "Since MRSA colonization leads to infection in a specific patient and is a risk factor for transmission of MRSA to other patients, rapid identification of those with MRSA colonization will reduce the risk of infection in colonized patients, by enabling their clinicians to intervene, and reduce the risk of patient-to-patient transmission by permitting isolation of those who are MRSA-colonized. Furthermore, this technology will markedly increase the rate at which community-associated or hospital-acquired MRSA patients are identified. Thus, more rapid isolation and treatment can occur. The multiple benefits of this rapid identification method will improve patient treatment, reduce the risk of transmission in healthcare settings, and reduce the burden of MRSA in U.S. hospitals."
References:
¹ BBL CHROMagar package insert. |
